OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries	492
Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer	389
Issue Information	213
The economics of advanced and unresectable hepatocellular carcinoma	162
New standard of care for multiple myeloma?	158
Best of both worlds? Linking comprehensive and noncomprehensive cancer centers	140
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis	104
Potential of circulating tumor DNA to refine immunotherapy	89
Reply to “Enhancing the role of social work in managing cancer risks among LGBTQ+ populations” and “The urgency of systematically acquiring sexual orientation and gender identity data to ensure equity	74
Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation	74
	73
Accelerated approval of multiple myeloma therapies	70
Issue Information	67
Top advances of the year: Neoadjuvant immunotherapy in melanoma	67
	64
	64
Issue Information	64
Issue Information	61
	60
Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care	59
New test for detecting cervical adenocarcinoma	57
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer	56
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient‐centere	56
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	55
Sharp rise in esophageal cancer and Barrett esophagus seen in middle‐aged people	52

Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3‐tyrosine kinase domain mutations: Prognostic implications of NPM1 co‐mutation	51
The critical need to implement and utilize patient‐reported measures of function in cancer care delivery	50
Development and validation of a machine‐learning–based pathomics nomogram for predicting recurrence of localized primary gastrointestinal stromal tumors after complete surgical resection: A retrospect	50
Updates on research and management of gastrointestinal stromal tumors in China	48
Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers	47
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non‐Indigenous men in a universal health care system	47
Understanding risk factors for cancer: What's new and how can it help reduce the cancer burden?	46
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer	46
Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality	46
What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?	46
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”	45
Erratum to “Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study”	45
Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”	45
Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”	44
Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing	43
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia	43
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases	42